Northside Hospital, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1970-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.northside.com
Clinical Trials
25
Active:0
Completed:12
Trial Phases
2 Phases
Phase 2:21
Not Applicable:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (23 trials with phase data)• Click on a phase to view related trials
Phase 2
21 (91.3%)Not Applicable
2 (8.7%)Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide
Phase 2
Not yet recruiting
- Conditions
- Hematologic Disease and DisordersHematopoietic Cell Transplant
- Interventions
- First Posted Date
- 2025-02-14
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06828796
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant
Phase 2
Withdrawn
- Conditions
- Myelodysplastic SyndromesAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2024-03-29
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Northside Hospital, Inc.
- Registration Number
- NCT06337331
- Locations
- 🇺🇸
Caitlin Guzowski, Atlanta, Georgia, United States
Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
Phase 2
Recruiting
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT06046248
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
CAR T-cell Therapy in Patients With Renal Dysfunction
Phase 2
Recruiting
- Conditions
- Non-hodgkin Lymphoma,B CellAcute Lymphoblastic Leukemia, AdultMultiple Myeloma
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05909059
- Locations
- 🇺🇸
Caitlin Guzowski, Atlanta, Georgia, United States
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
Phase 2
Recruiting
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05519579
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found